<span item_type="fundamental" item_id="7cb9687d7bef052d11344fed6b6973c9" counter_id="ST/US/KLTO" env="prod"></span><span item_type="announcement" item_id="550742252708238337" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.12.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -4.093 M.</p><p></p><h3>Segment Revenue</h3><p>The company did not generate any revenue for the three and six months ended June 30, 2025 and 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1907223/000121390025077684/ea0253157-10q_klotho.htm"></span></p><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: For the three months ended June 30, 2025, the net loss was $4,093,231, compared to $451,639 for the same period in 2024. For the six months ended June 30, 2025, the net loss was $6,327,213, compared to $1,123,683 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1907223/000121390025077684/ea0253157-10q_klotho.htm"></span></li><li><strong>Operating Expenses</strong>: Operating expenses for the three months ended June 30, 2025 were $1,892,852, compared to $395,607 for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $3,479,820, compared to $817,652 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1907223/000121390025077684/ea0253157-10q_klotho.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the six months ended June 30, 2025, net cash used in operating activities was - $3,522,178, compared to - $929,399 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1907223/000121390025077684/ea0253157-10q_klotho.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: For the six months ended June 30, 2025, net cash provided by financing activities was $11,889,383, compared to $1,895,424 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1907223/000121390025077684/ea0253157-10q_klotho.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Share-based Compensation</strong>: Share-based compensation for the three months ended June 30, 2025 was $390,195, compared to $37,514 for the same period in 2024. For the six months ended June 30, 2025, share-based compensation was $885,695, compared to $37,514 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1907223/000121390025077684/ea0253157-10q_klotho.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company is focused on developing essential medicines for chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders. It has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform, along with proprietary, patented technologies for gene therapy.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1907223/000121390025077684/ea0253157-10q_klotho.htm"></span></li><li><strong>Non-Core Business</strong>: The company terminated the acquisition agreement with SB Security Holdings, LLC, which was an internet-connected video doorbell service company.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1907223/000121390025077684/ea0253157-10q_klotho.htm"></span></li><li><strong>Priority</strong>: The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities to continue its development plans and operations. Without additional funding, there is substantial doubt about the company’s ability to continue as a going concern for twelve months from the date of these financial statements.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1907223/000121390025077684/ea0253157-10q_klotho.htm"></span></li></ul>

Klotho Neurosciences | 10-Q: FY2025 Q2 EPS: USD -0.12